A groundbreaking discovery by scientists in Singapore has unveiled a hidden defense mechanism employed by lung cancer cells, shedding light on why certain treatments become ineffective over time. This revelation could potentially revolutionize the way we combat drug-resistant lung cancer.
The Battle Against Lung Cancer: Uncovering a Stealthy Defense Mechanism
Lung cancer, a global health crisis, is often driven by mutations in the EGFR gene, leading to uncontrolled cell growth. In Southeast Asia, these mutations are prevalent in a common lung cancer type, adenocarcinoma, affecting up to 60% of cases. While targeted drugs initially offer hope, resistance inevitably develops, leaving patients with limited options.
Scientists have long been intrigued by the stability of the faulty proteins produced by mutant EGFR, which persist far longer than their normal counterparts. Why do these proteins evade degradation, allowing cancer to thrive?
Unveiling the Cancer Cell's Survival Strategy
In a comprehensive study published in Science Advances, researchers from the ASTAR Institute of Molecular and Cell Biology (ASTAR IMCB) conducted a genome-wide screen, analyzing over 21,000 genes to uncover the secret behind this stability. They discovered that cancer cells employ a clever tactic: flooding their surroundings with ATP, a molecule typically used for energy, to activate a receptor called P2Y2. This receptor, in turn, recruits a partner protein, integrin β1, to form a protective barrier around the mutant EGFR protein.
This barrier acts as a shield, preventing the faulty protein from reaching the cell's recycling center, where it would normally be broken down. As a result, the mutant protein remains active, driving cancer growth unchecked. The researchers confirmed this mechanism in human cancer tissue samples, finding elevated levels of P2Y2 and integrin β1 in tumors compared to healthy tissue.
A Potential Breakthrough: Disrupting the Defense System
The good news is that P2Y2, being located on the cell surface, presents an accessible target for drugs. By disrupting this protective system, scientists believe they can halt cancer progression. In laboratory models, the team demonstrated that removing the P2Y2 receptor led to a significant loss of the mutant EGFR protein in drug-resistant cancer cells.
Furthermore, they explored the potential of a natural compound, kaempferol, found in vegetables like kale and broccoli. Daily treatment with kaempferol in laboratory models with drug-resistant human lung tumors resulted in a substantial reduction in tumor size over 24 days. Importantly, this treatment specifically targeted cancer cells carrying EGFR mutations, leaving normal cells unaffected.
A New Approach to Overcoming Drug Resistance
Professor Wanjin Hong, a leading researcher at A*STAR IMCB and co-corresponding author of the study, emphasized, "By targeting the P2Y2 system, we're not just attacking the mutation itself but the entire support structure that keeps it stable. This approach offers a promising strategy to tackle drug resistance and potentially enhance the effectiveness of existing treatments."
This groundbreaking research, led by Prof. Hong, a recipient of the President's Science Award, involved a collaborative effort with researchers from various institutions, including the National University of Singapore and the National Cancer Centre Singapore, as well as international partners.
The findings open up exciting possibilities for the development of new therapies to combat drug-resistant lung cancer. However, it's important to note that further research and clinical trials are needed to translate these laboratory findings into effective treatments for patients.
What are your thoughts on this potential breakthrough? Could this new approach offer hope to those battling drug-resistant lung cancer? Feel free to share your opinions and insights in the comments below!
